NCT05690425 - A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

March 15, 2024

Study Completion Date

June 15, 2024

Conditions

Hematologic Malignancy

Interventions

DRUG

BC3402 Injection

Subjects will receive BC3402 as a single agent via intravenous infusion once every 3-weeks (Q3W),the dose of BC3402 was calculated according to the dose group and body weight of the subjects.

Trial Locations (1)

510630

RECRUITING

The First Affiliated Hospital of Jinan University, Guangzhou